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BACKGROUND: Monitoring antibiotic use in hospitals
was recognised as a priority by the European Union in
1998. However, most hospitals in the Europe currently
have very limited prescribing information systems.
METHODS: We compared two methods direct pharma-
cist monitoring and computerised records of drug supply
to six acute medical wards. The main outcome measure
was the number of patients exposed to glycopeptides. The
computerised system calculated used the modal pre-
scribed daily dose (PDD) divided by the average duration
of an intravenous antibiotic treatment course. Direct
pharmacist monitoring used individual record forms for
each patient prescribed glycopeptides.
RESULTS: Compared to the reports submitted from
direct monitoring the computerised estimate indicated
60% more use of glycopeptides. Limitations of both
systems were identiﬁed: 1. the use of average durations
of IV treatment can over estimate the number of courses
prescribed as the true duration for speciﬁc antibiotics 
may be longer than the average used; 2. PDDs may vary
depending on patient co-morbidities; 3. Data collection
by the direct method may be incomplete due to variabil-
ity in stafﬁng levels; 4. Paper records make data entry,
analysis and feedback time consuming and slow. The
major added value of direct pharmacist monitoring is
information about compliance with hospital policies.
Supply data showed a two-fold increase in glycopeptide
use in 18 months. Of 133 patients with completed forms
99 (74%) received glycopeptides for an appropriate indi-
cation but 14 (11%) of prescriptions outwith the policy
had been approved by Microbiology or Infectious Dis-
eases, leaving only 20 (15%) inappropriate prescriptions.
CONCLUSIONS: Ward supply data provides a conve-
nient method for checking the completeness of direct
patient monitoring. Paper-based monitoring is slow to
process. As a consequence of this study, funding is being
sought to facilitate the analysis and feedback of direct
monitoring through a network of intranet linked termi-
nals across the hospital.
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During the post-menopausal years, the long-term conse-
quences of estrogen loss, namely coronary heart disease
(CHD), osteoporosis and osteoporosis-related fractures,
have an important effect on a woman’s morbidity and
mortality. In absence of randomized trials that include
clinical endpoints for all preventive strategies, a decision-
model is useful to predict the effect of treatment.
OBJECTIVE: To predict life expectancy (YOL) taking
into account CHD, hip fracture and breast cancer risk
using a Markov model based on data from the literature
and Canadian health statistics.
METHODS: The model was used to compare predicted
YOL of HRT based on low and high risk factor proﬁles
post-menopausal women. Under scenario 1, we assume a
risk reduction of 35% after 5 years of HRT and of 40%
after 10 years of treatment; we also assume that HRT
have a 20% and 50% of hip fracture risk reduction after
5 years and 10 years of treatment, and ﬁnally the
increased risk of breast cancer was at 35% in women
taking HRT for ﬁve years or longer. Under scenario 2:
similar assumptions were done except that we assume a
1% increase of risk of CHD during the 2 years following
the initiation of HRT.
RESULTS: Predicted YOL for low risk of CHD, hip frac-
ture and breast cancer of women aged 45, 55, 65 and 75
years old were at 0.52, 0.24, 0.17 and 0.010 under 
scenario 1, and these values were at 0.47, 0.23, 0.16 and
0.02 for scenario 2. The corresponding ﬁgures for high
risk of CHD, hip fracture and breast cancer for women
aged 45, 55, 65 and 75 years old were at 1.65, 0.64,
0.014 and -0.11 for scenario 1, and at 1.99, 0.87, 0.12
and -0.22 for scenario 2, respectively.
CONCLUSION: We suggest that HRT initiation should
take into account the risk proﬁle of post-menopausal
women and their age.
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OBJECTIVE: To compare the economic cost of adding
sildenaﬁl to treat selective serotonin reuptake inhibitor
(SSRI)-induced erectile dysfunction (ED) with the cost of
switching patients to another SSRI or discontinuing all
depression pharmacotherapy.
METHOD: Based on our “real world” experience at an
academic medical center, we performed an economic
analysis on a hypothetical cohort of 1000 patients taking
SSRIs. In our model, patients received SSRIs for an acute
period of 60 days followed by continuation treatment for
120 days. We employed several evidence-based assump-
tions and used standard costs of antidepressants, silde-
naﬁl, and unit costs for physician visits within a managed
care environment and cost-of-illness methodology to 
calculate the annualized cost of depression in the SSRI
discontinuation group.
RESULTS: In our model, after 6 months of SSRI treat-
ment, the sildenaﬁl add-on group had the lowest cost 
estimates ($112/patient/month) compared with the group
